Immunogenicity and Safety of a Novel MMR Vaccine (Live) (Freeze-dried): Results of a Phase II Clinical Trial
Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 1
Abstract
ABSTRACT Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as part of clinical development programme to evaluate the safety and immunogenicity of the novel vaccine in small cohort of target population before conducting the larger comparative phase III study. Aim: To evaluate the immunogenicity and safety of the singledose and multi-dose formulations of the novel vaccine. Materials and Methods: One hundred and twenty three healthy children 15-18 months of age were administered a single dose of the novel MMR vaccine from either the single-dose or the multi-dose formulation. Immunogenicity of the vaccine was assessed by measuring IgG antibodies against the measles, mumps and rubella viruses before and six weeks after the vaccination. Safety of the vaccine was assessed by recording adverse events during the six week study period. Results: The seroconversion rate for anti-measles and antimumps antibodies was 100% while that for anti-rubella antibodies was 98.9% after the MMR vaccination. There was no difference in the seroconversion rates in the subjects receiving the MMR vaccine either from the single-dose or the multi-dose formulation. The Geometric Mean Titre (GMT) of anti-measles, anti-mumps and anti-rubella antibodies was 3154.0 mIU/mL, 90.6 EU/mL and 141.7 IU/mL, respectively. The vaccine was well tolerated, 28 subjects (out of 123) reported 43 adverse events during the study (adverse event rate of 21.8%). The most common adverse event reported during the study was fever in 19 subjects (15.4%) followed by rash and rhinorrhoea in five subjects (4.1%) each. Conclusion: The results of this phase II clinical trial show that both the single-dose and the multi-dose formulation of the novel MMR vaccine are immunogenic and well tolerated by healthy paediatric subjects aged 15-18 months.
Authors and Affiliations
Rajesh Joshi, Neeta Hanumante, Uma Nayak, Shalaka Agarkhedkar, Paresh Thakkar, Jayesh Sanmukhani, Ravindra Mittal
Keywords
Related Articles
- EP ID EP523933
- DOI 10.7860/JCDR/2018/29855.11125
- Views 78
- Downloads 0
Qualitative and Quantitative Comparison of the Remineralisation Potential of Three Suitable Materials-An In vitro SMH and SEM Study
ABSTRACT Introduction: Concept of preventive dentistry is the base for this study which focuses on daily treatment of tooth for prevention of caries using some commercially available remineralizing agents. The mechanism...
A Successfully Treated Case of Criminal Thallium Poisoning
Thallium was once commonly used as a household rodent or ant killer, but many countries have banned such use due to unintentional or criminal poisonings of humans. A common initial clinical manifestation of thallium pois...
A Rare Presentation of Metastasis to the Thyroid Gland
The thyroid gland has a rich vascular supply. However, metastasis to the thyroid is exceedingly rare. The most common tumours that metastasize to the thyroid are breast and lung. The incidence of metastasis is on the ris...
Story of a Giant Endometrial Polyp in Asymptomatic Postmenopausal Female
Endometrial polyps are localized overgrowth of endometrial glands and stoma through the uterine cavity. They are associated with postmenopausal bleeding, infertility and menorrhagia and are affected by unbalanced oestrog...
Idiosyncratic Liver Injury due to Rivaroxaban
Rivaroxaban is an oral direct factor Xa inhibitor that has been used for the primary and secondary prophylaxis of thromboembolic disorders. Once daily dosing makes it an attractive alternative when compared to other Nove...